CloTho tells you what you can win now, what needs work first, and what to walk away from. Grants, R&D incentives, accelerators, cloud credits and investors across North America, Europe, the Middle East, APAC, LATAM and Africa.
Three weeks of evidence assembled, then the clause that excludes you turns up in the first paragraph.
Nobody owns the funding calendar, so the cut-off passes and you find out in December.
Equity given away for money that was sitting in a programme nobody on the team had seen.
Everyone offering to help is paid when you apply, not when you skip.
And the clause that disqualifies you was readable on day one, in the first paragraph of the rules.
Your map is a living board. Programs open and close, your company changes, and the map moves with it.
Stage, jurisdiction, founder residency, product, revenue, R&D, IP, what you've already tried. Fifteen minutes — and it's the part that makes eligibility real instead of approximate.
Every route comes back with a verdict, an amount you can plan around, the reason behind it, and a link to the official source. Four lanes, no scoring theatre.
Open a route, see its requirements and deadline, start the application without leaving CloTho. Track what's submitted, what's waiting, and what just opened.
Fifteen minutes, no documents to upload. These are the fields eligibility turns on — and the reason a generic tool gets your case wrong.
One company, one board. Every route we check, sorted into four lanes — each with a verdict, an amount you can plan around and the next concrete step.
Three things in this structure that decide the rest
Dual-use programmes check control by non-associated third countries. 24% sits below the control threshold, but an ownership-and-control declaration is required before you can be assessed.
Documents, not restructuring · ~2 weeksThe product falls under EU Regulation 2021/821. An export authorisation is needed before the first sale outside the EU, and several programmes check that it exists.
Not a funding blocker, but a condition · 6–10 weeksThe Luxembourg IP box — a 6.75% effective rate — needs qualifying IP, which means a patent and not software copyright. Two further routes want a filed application.
A provisional filing opens three routes · 4 weeksApply this cycle
Book the pre-application meeting
Apply this week
Missing: Luxinnovation certificate + closed round
Missing: ownership declaration
Missing: filed patent
Signal: TRL 5
Signal: call opens
Ineligible — structure
Too late — revisit next cut-off
Ineligible — jurisdiction
Skip — price
Illustrative example built on real programmes. Amounts, deadlines and verdicts are indicative — your board is checked against your own company.
Three points where you decide, not the calendar
If it is a no, the February capacity moves to DIANA rather than sitting idle. The plan does not depend on any single route.
Young Innovative Enterprise co-matches private capital, up to €1m. Without a round, the ceiling of this board is €352k.
The two bank pilots are the gate into EIC. Reach it and a €2.5m route opens; miss it and the year still closed at €352k.
€352,000 in twelve months, zero dilution— with €1.4m more in the pipeline. A €1.5m pre-seed at 18% would have given you less and cost you the company.
Every route on this board is correct, the amounts are right and the deadlines are met — and you would still be €12,000 short in April, one month before €260,000 lands. A funding plan that ignores the calendar is not a plan.
Three ways to close five weeks
€22k of cloud and compute moves off the burn from October, roughly €2.4k a month. On its own it covers about half the gap and costs nothing but the application.
Luxembourg banks and SNCI lend against an awarded grant. It closes the gap outright and the cost is interest for five weeks — not a share of the company.
Six months of a smaller burn clears April without borrowing anything. It is the cheapest option and the one that has to be decided earliest.
RDI aid is paid against proof of spend. You have to spend the €400k project budget before the €180k comes back, which is why it shows in May rather than at award. Reimbursement is a cash-flow question, not a funding question — and it is the one that catches most first-time applicants.
Non-dilutive money is not slow money. It is money with a schedule.The board is only worth anything if that schedule fits your runway — which is why both are on the same screen, and why the gap is shown rather than smoothed over.
Five questions, no email. These are the fields eligibility actually turns on — the ones a keyword search never asks about.
Where is the company incorporated?
And in which country?
Do the founders live where the company is registered?
What stage is the company?
Are you spending on R&D, cloud or compute?
Answer all four and we will tell you, plainly, whether this is worth your time.
Not a research report nobody reads. Four things you can put in front of your co-founder and start moving on the same day.
Every route sorted into four lanes so the order of attention is obvious before you read a single line of detail.
The applications you are not eligible for, and the ones where the cost exceeds the award — each with the sentence that ends the debate.
Cut-offs, rolling deadlines and the date preparation has to start — so a route never closes while you were busy shipping.
One concrete action per live route and the person on your team who carries it. Nothing on the board is a task without a name.
Most tools cover one. A grant database will never tell you that $150k of cloud credits is faster, larger, and closes this month.
National and regional programs. Eligibility, deadlines, co-financing rules and the evidence each one expects before you write a word.
Credits and reliefs, patent box, payroll offsets. Which of your spend qualifies, and what has to be documented to survive review.
Equity terms, stage fit, geography, cohort dates — including which ones are worth applying to and which are a three-month distraction.
AWS, Azure, Google, OpenAI, NVIDIA and the rest. Often larger and far faster than a grant, and almost nobody treats them as funding.
Founder networks, university partnerships, technology transfer offices and clusters — with the actual route in, not a promise of an intro.
Angels, funds and venture debt matched to your stage and sector, plus a straight answer on whether raising now is your strongest move.
Both give you names. Neither can tell you whether your company clears the rules — which is the only part that decides anything.
I ran corporate budgets at €7.2 billion scale. I bought technologies and companies, applied for grants, negotiated with governments, and built the partnerships that changed what a business could reach.
Built by a founder, for founders.
No success fee, no percentage of what you raise, no commission from any program on the board.
Everything the board does, for one company, for a full year.
A second pair of eyes on a decision you have already made on the board.
Once the board is set: writing and filing the applications, finding your consortium partner, running grant reporting, building R&D documentation or setting up the entity — flat fees, quoted per case.
Twelve months from the day your map is ready. Beta price held for everyone who joins before public launch, and you pay when the map is ready — not to request access.
$290 for the year during the beta — one company, everything the board does, and the board stays live for twelve months. A 60-minute working session with a funding strategist to walk through it together is an optional $150, added only if you want it. No success fee, no percentage of anything you raise, and no card charged until your map is ready.
The intake takes about fifteen minutes and the first board comes back the same day. After that it's live: when a window opens, a rule changes, or your company crosses a signal you set, the affected routes update and you're told which ones moved.
Then the board says so, and that's a real answer worth having early. Some companies are too young, too small, or in a jurisdiction with thin programs. We'd rather show you an honest four-route board than pad it out to twenty.
No. A database returns everything matching a keyword. CloTho returns a decision: which routes you qualify for today, which need work first, which to watch, and which to drop — checked against your company, not against a search term. It also covers R&D incentives, cloud credits, accelerators, communities and investors, which grant databases don't.
The map never depends on it. We're paid for the map, not for outcomes — that's what lets us tell you to skip something. The board takes you to the door with the requirements, the deadline and the evidence list. If you'd rather not walk through it yourself, we'll write and file at a flat fee, quoted per case. Never a percentage of what you raise.
No. Nobody honestly can. We guarantee the delivery — a complete, sourced, dated map of the routes open to your company — never the decision of a program, fund or agency on it.
North America, Europe, the Middle East, Asia-Pacific, Latin America and Africa — including the programmes that turn on founder residency and entity structure, the part that trips up every matching tool. Depth varies by country: North America and Europe are the deepest today, and the board tells you plainly when your country's side of it is thin rather than padding it out. Tell us where you're incorporated when you request access and we prioritise by where demand actually is.
It builds your map and nothing else. It isn't sold, isn't shared with programs or investors, and isn't used to train anything. Delete it and your account at any time.
Ask for access and we'll open it for you.
No card, no deck, no call. One email when your access is open.